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Abstract
Purpose Malignant fungating tumors are neoplastic tumors
associated with skin ulcers, which are susceptible to microbial
colonization. Bacterial infection and proliferation may lead to
malodor causing distress to patients. Metronidazole—an ef-
fective agent against anaerobes—may contribute to deodori-
zation and improvement in quality of life (QOL). This study
investigated the efficacy and safety of topical metronidazole
0.75% gel for alleviation of malodor in anaerobically infected
fungating neoplastic tumors.
Methods This was a multicenter, open-label, non-controlled,
phase III study including subjects aged 20 years or older with
cutaneous fungating tumors releasing malodor (minimum
score of 2 (mildly offensive smell) on a scale from 0 (no smell)
to 4 (extremely offensive smell) based on investigator’s as-
sessment). Subjects applied metronidazole 0.75 % gel once or
twice daily at the investigator’s discretion for 14 days. Success
was defined as an odor score of 0 or 1 at day 14, as assessed by
the investigator. Patient satisfaction was assessed using a sat-
isfaction questionnaire. Adverse events (AEs) that occurred
after application of metronidazole 0.75 % gel were also
reported.
Results A total of 21 subjects at a median age of 65.0 years
were enrolled. The success rate of deodorization at day 14 was
95.2 % (20/21 subjects). The patient satisfaction assessment
showed that 71.4 % (15/21) of subjects were markedly or
moderately improved. The treatment was well tolerated with
only two AE cases of skin neoplasm bleeding (one mild and
one moderate).
Conclusions Metronidazole 0.75 % gel is an effective and
safe treatment for deodorization of malodorous fungating
tumors.
Keywords Topical metronidazole .Malodorous fungating
tumors . Odor . Skin ulcer . Clinical trial
Introduction
Malodors associated with ulcerating tumors are reportedly
caused by the odor of anaerobic infections of fungating
wounds and the odor of fatty acids produced in necrotizing
cancer tissue [1, 2]. In addition to emotional distress caused by
the appearance of the fungating wound, the large amount of
exudate, pain, and constant bleeding risk, patients with mal-
odorous fungating tumors also suffer from low self-esteem,
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social isolation, and low quality of life (QOL) [3].
Furthermore, the families and medical caregivers of patients
with malodorous fungating tumors may avoid close interac-
tions with the patient due to the odor.
It is well known that anaerobic bacteria cause malodors
in fungating wounds and that the antibacterial drug met-
ronidazole (MTZ) is effective for treating malodorous
fungating wounds [4, 5]. Furthermore, the topical applica-
tion of MTZ is recommended in Symptom Relief in
Terminal Illness, published by the World Health
Organization (WHO; WHO Library Cataloging-in-
Publication Data, 1998) and the 2001 curriculum
BOptimizing Cancer Care: The Importance of Symptom
Management,^ published by the American Society of
Clinical Oncology (ASCO) [3, 6, 7]. Topical MTZ has
been approved and marketed for the treatment of malodor-
ous fungating wounds only in the United Kingdom (UK).
In Japan, where topical MTZ is yet to be approved, each
medical institution prepares special topical MTZ formula-
tions for patients with malodorous fungating tumors [5, 8,
9].
In 2006, we surveyed medical facilities certified by the
Japanese Breast Cancer Society to understand the current
prescription status and dosage of topical MTZ formula-
tions for patients with malodorous fungating wounds due
to breast cancer. Data from 313 responding facilities re-
vealed that 80 (26 %) facilities formulated topical MTZ
for malodorous fungating wounds in patients with breast
cancer [10]. Also in 2010, the Japanese Society of
Hospital Pharmacists surveyed 382 member institutions
about the use and preparation of topical agents for patients
with malodorous fungating tumors and revealed that 317
(83 %) of the institutions used or prepared topical agents
for malodorous fungating wounds. Among the 317 institu-
tions, 264 (83 %) formulated topical MTZ and 266
(84 %) await commercialization [11].
To realize the commercialization of topical MTZ, the
Japanese Society for Palliative Medicine and the Japanese
Society for Pharmaceutical Palliative Care and Sciences
filed a petition to the Ministry of Health, Labour and
Welfare (MHLW) in 2010. Based on the discussion in the
6th Evaluation Committee on Unapproved or Off-label
Drugs with High Medical Needs,1 MHLW commissioned
the Galderma Company (Tokyo, Japan) to develop topical
MTZ. Galderma agreed to the commission and subsequent-
ly conducted a phase III clinical study to investigate the
efficacy and safety of topical MTZ 0.75 % gel (GK567)
in patients with malodorous fungating tumors.
Methods
Trial design
An open-label, uncontrolled, multicenter, phase III study was
conducted from April to December 2012 to evaluate the effi-
cacy and safety of MTZ 0.75 % gel (GK567) applied for 14
consecutive days.
Participants
Study participants met the following criteria: in- or outpatients
aged ≥20 years with fungating tumors that were possibly in-
fected; malodor corresponding to 2 or higher on the odor scale
of 0–4 as judged by the investigators; skin ulceration requiring
a daily dose of ≤30 gMTZ 0.75 % gel (for patients with breast
cancer, the ulcer size should be smaller than one of the
breasts); an Eastern Cooperative Oncology Group (ECOG)
performance status of ≤3; and an anticipated survival of
≥3 months.
Exclusion criteria were the following: (1) current sys-
temic administration of antibiotics or administration in the
last 2 weeks; (2) current local or extended application of
MTZ 0.75 % gel or other topical antibacterial agents in
the past week; (3) current administration of topical agents
for fungating tumors; (4) patients with a scheduled change
in concurrent cancer therapy during the study period; (5)
those with malodorous fungating wounds not in contact
with tumor tissue or those with fungating tumors invading
bone tissue; (6) allergy or hypersensitivity to MTZ; (7)
using ritonavir, disulfiram, warfarin, or lithium (these in-
teract with MTZ) or unable to abstain from alcohol during
the study period; (8) serious cardiovascular diseases,
hemodyscrasia (except for idiopathic thrombocytopenic
purpura), or central or peripheral organic neurological dis-
orders; or (9) pregnant or breastfeeding women or women
planning to conceive during the study period.
Intervention
After removing the container label, Rozex® gel 0.75 %
(Galderma) was used as the MTZ 0.75 % gel in the present
study. MTZ 0.75% gel was applied once or twice daily up to a
maximum daily dose of 30 g for 14 days. Fungating wounds
were cleaned thoroughly and covered with a dressing material
such as gauze, silicon gauze, or wound dressing coated with
topical MTZ.
The systemic and topical antibiotics administration
and any topical treatments on the fungating wound, ex-
cepting MTZ 0.75 % gel, were prohibited during the
drug application period.
0 Ministry of Health, Labour and Welfare, the 6th Evaluation Committee
on Unapproved or Off-label Drugs with High Medical Needs, http://
www.mhlw.go.jp/stf/shingi/2r9852000000w1az.html
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Primary endpoints: improvement of score of odor
At the time of screening, before (baseline or day 0) and after
application of MTZ 0.75 % gel (days 7 and 14), the malodor
of fungating wounds was scored by the investigators, nurses
(or study coordinators), and patients on 5 scale of 0 to 4
(0 = no smell; 1 = smell present but not offensive, slight smell
close to the ulcer about 20 cm; 2 = mildly offensive smell,
more pronounced smell close to the ulcer about 20 cm;
3 = moderately offensive smell, at the bedside about 1 m;
4 = extremely offensive smell, at the entrance of the room).
The success rate was defined as the percentage of patients
whose odor was scored 0 or 1 by investigators on day 14 (or
at the time of premature study termination).
Secondary endpoints
Clinical examination of fungating wounds
At the time of screening, on day 0 (pre-administration base-
line), and on post-administration days 7 and 14, fungating
wounds were evaluated by investigators based on 4 scale on
frequency of dressing changes of 0 to 3 (0 = none, no
discharge/once daily; 1 = mild, dressing need to be changed
twice daily; 2 =moderate, dressing need to be changed 3 times
daily; 3 =marked, dressing need to be changed >3 times daily/
bloody). The amount of exudate was assessed by examining
the frequency of dressing changes per day. The nature of the
exudate, such as purulent, serous or blood-stained fluid, was
recorded.
Pain assessment
At the time of screening and on days 0, 7, and 14, the patients
evaluated pain of the fungating wound in the last 24 h using a
100-mm visual analog scale (VAS) (0 mm, no pain; 100 mm,
worst imaginable pain).
Bacteriological testing
On days 0 and 14 (or at the time of premature study termina-
tion), samples were collected from the area of the wound with
the most severe inflammation and exudate (usually around the
center) for the identification and semi-quantitation of the caus-
al bacteria.
Overall improvement in patient satisfaction
After clinical examination on day 14 (or at the time of prema-
ture study termination), a patient satisfaction survey was con-
ducted with the involvement of patients and/or their families.
By comparing the data with baseline data, the investigator
categorized the change in patient satisfaction as markedly
improved, moderately improved, slightly improved, no
change, or worsened.
Pharmacokinetics
Tomeasure the plasma concentration ofMTZ and estimate the
total drug exposure around the time of its peak (Tmax), blood
was sampled before and after (at two time points between 2–
8 h) the application of MTZ 0.75 % gel on day 7 and at the
time of hospital arrival on day 14. A validated high-
performance liquid chromatographic method (limit of quanti-
tation, 2 ng/mL) was used to determine the plasma concentra-
tions and pharmacokinetic parameters of MTZ: Ctrough, Cmax,
Tmax, and partial AUC for day 7 and Ctrough for day 14.
Safety
Adverse events were recorded during drug application. In ad-
dition, hematological (white blood cell, red blood cell, hemo-
globin, hematocrit, and platelet) and blood chemistry (creati-
nine, urea nitrogen, total bilirubin, glutamic-oxaloacetic trans-
aminase (aspartate aminotransferase), glutamic-pyruvic trans-
aminase (alanine aminotransferase), lactate dehydrogenase, γ-
glutamyl transpeptidase, and alkaline phosphatase) examina-
tions were performed on days 0 (baseline) and 14 (or at the
time of premature study termination).
Sample size
Odor improvement was considered to be successful if scored 0
or 1 by the investigator on day 14 or at the time of premature
study termination, and the proportion of patients with an odor
score of 0 or 1 was defined as the success rate. The present
clinical study was designed to test our hypothesis that the
success rate would not fall below 70 %. Based on the report
of Finlay et al. [12], the improvement rate would be estimated
at approximately 90 % after a 2-week application. To verify
with a probability of 90 % that the 95 % confidence interval
(one side) would exceed 70 %, the required sample size was
20 patients, as determined using normal approximation to the
binomial distribution.
Ethical considerations
This study was approved by the internal review board of each
institution and performed in accordance with the Declaration
of Helsinki and the Ministerial Ordinance on Good Clinical
Practice for Drugs (GCP) of Japan. Informed consent was
obtained from all individual participants included in the study.
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Results
Subjects
Subjects were 21 patients with breast cancer (median age,
65.0 years; range, 39–82 years), of which 20 completed the
study. The application ofMTZ 0.75% gel was discontinued in
one patient on day 7 because of an increase in the amount of
exudate from the fungating wound. Because no significant
deviations from the original clinical trial implementation plan
were observed, data from all 21 patients were used in the
analysis of drug safety.
Demographics and baseline characteristics are shown
in Table 1; 5 (23.8 %) patients had stage III tumors and
16 (76.2 %) had stage IV. The mean area of the
fungating wounds was 68.6 ± 35.4 cm2 (range, 4–
140 cm2), and 16 (76.2 %) patients had not received
previous treatment for malodor due to the fungating
tumor (Table 1).
Application of study drug
The mean duration of MTZ 0.75 % gel application was
13.8 ± 1.6 days, and the total dose was 311.7 ± 96.8 g. The
gel was applied 1.46 ± 0.41 times daily up to a daily dose of
22.6 ± 6.4 g (range, 11–30 g).
Primary endpoint: improvement of odor score
The odor scores given by the principal investigator on day 14
are shown in Table 2. The clinical success rate (score 0 or 1)
was 95.2 % (20 of 21 patients), and the 90 % confidence
interval (exact two-tailed significance level) was 79.3–
99.8 %, verifying the study hypothesis that the rate of success
would not fall below 70 %.
Differences in scores given by different evaluators are
shown in Fig. 1. The scores were comparable between the
investigators and nurses. The scores given by patients were
slightly less than those given by the investigators or nurses.
However, the temporal profiles of changes in scores were
similar among the three groups.
Secondary endpoints
Clinical findings of fungating wounds
The mean ± SD odor scores of fungating wounds were
1.6 ± 0.9 for day 0, 1.1 ± 1.0 for day 7, and 0.9 ± 0.9 for
day 14. Exudate was characterized as purulent in 6 patients,
serous fluid with blood in 5, and serous in 4 on day 0; serous
in 12 patients on day 7; and serous in 10 patients on day 14,
demonstrating an overall reduction in purulent fluid and an
increase in serous fluid during the study.
Pain
On the VAS, the mean ± SD of pain was 28.3 ± 29.1 mm on
day 0 (baseline), 25.9 ± 27.1 on day 7, and 22.2 ± 25.3 on day
14, showing no change from baseline to day 7 or day 14.





Race Asian 21 (100.0)
Age (year) Median 65.0
Range 39–82
Mean ± SD 64.4 ± 12.2
<30 0
30 to <40 1 (4.8)
40 to <50 2 (9.5)
50 to <60 3 (14.3)
60 to <70 8 (38.1)
≥70 7 (33.3)
Height (cm) Mean ± SD 154.51 ± 5.44
Median 154.10
Range 145.0–166.0
Weight (kg) Mean ± SD 52.67 ± 9.38
Median 50.00
Range 35.6–79.6
Previous treatment for odor No 16 (76.2)
Yes 5 (23.8)
Tumor stage Stage III 5 (23.8)
Stage IV 16 (76.2)
Tumor type (location) Breast cancer 21 (100.0)
Other cancer 0
Area of fungating wound (cm2) Mean ± SD 68.6 ± 35.4
Median 75.0
Range 4–140
Table 2 Evaluation of odor by investigatorsa, (n = 21)
Number (%)





Mean ± SD, 0.5 ± 0.7
a On day 14 or at the time of premature study termination
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Bacteriological findings
Changes in bacteriological findings and identified bacte-
ria are shown in Tables 3, respectively. Anaerobic bac-
teria detected in nine patients on day 0 were not detect-
ed on day 14 (or at the time of premature study termi-
nation). However, one novel anaerobic bacterium was
detected in one of the patients on day 14 (or at the
time of termination). No significant changes were ob-
served in the profiles of aerobic bacteria.
Overall improvement in patient satisfaction
Table 4 shows the patient satisfaction on day 14 (or at
the time of premature study termination). Improvement
in patient satisfaction was graded as markedly or mod-
erately improved in 15 patients (71.4 %), indicating that
patients were satisfied with the efficacy of MTZ 0.75 %
gel for malodorous fungating tumors.
Pharmacokinetics
The pharmacokinetic parameters of MTZ are shown in
Table 5. On day 7, the mean Cmax of MTZ was 852 ng/mL
(range, 136–2872 ng/mL). The mean C t rough was
380 ± 281 ng/mL on day 7 and 510 ± 565 ng/mL on day 14.
The coefficient of variance of Cmax was 82 % on day 7, and
that of Ctrough was 74 and 111 % on day 7 and day 14, respec-
tively, showing a large variance in the pharmacokinetic pa-
rameters. This suggests a large variation in the plasma con-
centrations of MTZ existed among the patients.
Safety
In total, 28 adverse events were observed in 15 patients
(71.4 %); only two of these were bleeding from
neoplastic skin lesions (one mild and one moderate
severity), which were considered to be related to MTZ
0.75 % gel by the investigator and the other AEs were
unrelated. Three serious AEs in one patient (4.8 %)
were observed, but these were judged to be unrelated
to MTZ 0.75 % gel; one of these occurred prior to
application of the drug. No deaths were reported in
the study.
Discussion
In this study, the safety and efficacy of 14-day consecutive use
of topical MTZ 0.75 % gel on malodorous fungating wounds
were investigated in 21 female patients with breast cancer. The
subjects of this study were patients with a fungating tumor and
malodor from infection, and other types of malodorous
fungating tumors were not evaluated. In Japan, most studies
have investigated the effects of topical MTZ on malodorous
fungating tumors of breast cancer patients [5, 8, 13–29], but
few investigated the efficacy and safety of topical MTZ on
malodorous fungating wounds that are unrelated to breast
cancer [30–34].
The mean size of skin ulceration was 68.6 ± 35.4 cm2
(range, 4–140 cm2), and this might have been due to the pre-
scribed dosage of MTZ 0.75 % gel, that is, once or twice daily
and a maximum of 30 g/day. Mean daily dose was
22.6 ± 6.4 g, and the daily dosing frequency was
1.46 ± 0.41. Therefore, we estimated that mean single dose
was approximately 15.5 g, and the mean dose per unit area of
skin ulcer was 0.23 g/cm2. The latter is roughly equivalent to
0.5 fingertip unit (FTU) because 1 FTU, defined as the amount
of ointment applied from the distal interphalangeal joint to the
tip of the index finger, is approximately equivalent to 0.5 g
Day 0 Day 7 Day 14
(21) (21) (20)
Day 0 Day 7 Day 14
(21) (21) (20)
Day 0 Day 7 Day 14
(21) (21) (20)
Fig. 1 Odor scores by patients, nurses, and investigators. 0 no smell; 1
smell present but not offensive, slight smell close to the ulcer about
20 cm; 2 mildly offensive smell, more pronounced smell close to the
ulcer about 20 cm; 3 moderately offensive smell, at the bedside about
1 m; 4 extremely offensive smell, at the entrance of the room. () = n
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[35]. In general, 5 FTU of ointment is needed to treat a skin
ulcer of 10 cm2.
By investigator evaluation, improvement of malodor
was successful in 95.2 % (20/21) of patients. This is
consistent with the reported estimate that malodor would
improve in 95 % of patients after 2 weeks of MTZ
0.75 % gel by Finlay et al. [12], and verified our study
hypothesis that the rate of success in this study would
not fall below 70 %. Improvement was not successful in
one patient after she requested discontinuation of MTZ
0.75 % gel on day 7 because of an increase in exudate.
However, improvement of odor was successful in all the
patients who completed the 14-day application of the
drug. The study of Finley et al. [12] enrolled 20 pa-
tients with malodorous fungating tumors, including 13
breast cancer patients, one for each of oral carcinoma,
fungating basal cell carcinoma, carcinoma prostate, ma-
lignant ulcer, leg sarcoma, carcinoma tongue, and met-
astatic carcinoma; malodor was improved in 14 (88 %)
of the 16 patients (unpublished data). A similar im-
provement was observed in Japanese patients in the
present study.
Based on the evaluation by patients, nurses, and inves-
tigators, the number of patients with a score 2 or above
(corresponding to mildly to extremely offensive smell) was
12, 17, and 21, respectively, on pre-application day 0,
while it was 0, 1, and 1 on day 14. Olfactory adaptation
was believed to be the reason for the small number of
patients who gave a score of 2 or above on day 0 com-
pared with the number of nurses and investigators who
gave similar scores. The difference between the mean odor
score on day 0 and the score on day 14, as assessed by
the patients themselves, nurses, and investigators, was re-
spectively −1.7 ± 1.1, −2.1 ± 1.1, and −2.2 ± 0.7, indi-
cating that the change in odor severity was perceived to
be greater by third parties, that is, nurses or investigators,
than by patients.
The exudate from fungating wounds changed from being
purulent to serous during the course of treatment. This finding
is supported by the bacteriological findings that anaerobic
bacteria detected in nine patients on day 0 were no longer
detectable on day 14 (or at the time of premature study termi-
nation), suggesting that MTZ 0.75 % gel effectively reduced
the number of anaerobic bacteria in the wounds.
Using the VAS, the mean values of pain were not changed
from baseline to day 7 or day 14. The survey of patient or
family satisfaction conducted on day 14 showed that 15
(71.4 %) patients perceived the effect of MTZ 0.75 % gel on
malodor to be quite or very effective, while the survey of
nurses or investigators indicated the deodorant effect in all
21 patients was quite or very effective. These findings suggest
that all involved parties were satisfied with the effect of MTZ
0.75 % gel.
The results of this study showed that the level of systemic
exposure of ≤30 g MTZ 0.75 % gel daily for treating a
fungating tumor of 4–140 cm2 in size did not exceed the
systemic exposure level of 250 mg MTZ taken orally as a
Table 3 Summary of bacteriological findings (n = 21)
Category/bacterial species Baseline day 0 Post-applicationa
Aerobic bacteria 20 (95.2) 19 (90.5)
Acinetobacter baumannii complex 1 0
Aeromonas sp. 1 0
Bacillus sp. 2 1
Citrobacter koseri 1 1
Coagulase(−)staphylococcus 2 1
Corynebacterium sp. 7 8
Enterobacter aerogenes 1 0
Enterobacter cloacae 2 0
Enterococcus durans 0 1
Enterococcus faecalis 1 0
Escherichia coli 1 2
Gemella morbillorum 1 0
Klebsiella pneumoniae 2 1
Proteus mirabilis 2 3
Pseudomonas aeruginosa 7 7
Pseudomonas sp. 1 1
Staphylococcus aureus 9 8
Streptococcus agalactiae (group B) 3 2
ß-Streptococcus (group G) 0 1
Gram-negative aerobic bacteria 1 2
Anaerobic bacteria 9 (42.9) 1 (4.8)
Bacteroides caccae 1 0
Bacteroides fragilis 1 0
Fusobacterium sp. 1 0
Peptostreptococcus asaccharolyticus 2 0
Peptostreptococcus magnus 2 0
Peptostreptococcus micros 2 0
Peptostreptococcus prevotii 2 0
Peptostreptococcus sp. 0 1
Peptostreptococcus tetradius 2 0
Prevotella intermedia 2 0
Streptococcus constellatus 1 0
Streptococcus intermedius 1 0
Gram-negative anaerobic bacteria 12 20
a On day 14 or at the time of premature study termination
Table 4 Overall
improvement in patient
satsfactiona, (n = 21)
Category Number (%)
Markedly improved 9 (42.9)
Moderately improved 6 (28.6)
Slightly improved 5 (23.8)
No change 1 (4.8)
Worsened 0
a On day 14 or at the time of premature
study termination
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single dose. In addition, no systemic side effects were ob-
served, demonstrating its safety, provided that the recom-
mended dosage and frequency of administration are followed.
The two cases of bleeding from the neoplastic skin lesion,
which were considered to be related to MTZ 0.75 % gel, were
caused by the dried and solidified gel injuring the ulcer during
the dressing change. To prevent such bleeding, the fungating
wound and dried MTZ 0.75 % gel should be moistened and
softened with clean water before peeling off the dressing.
In summary, this clinical study showed that MTZ 0.75 %
gel is safe and highly effective in reducing the intensity of
malodors from fungating wounds in breast cancer patients.
After 14 days of application, the drug increased levels of sat-
isfaction among the patients, their families, and medical per-
sonnel. Finlay et al. [12] reported the efficacy and safety of
MTZ 0.75 % gel in malodorous fungating tumors of not only
breast cancers but also other cancers. In UK, MTZ 0.75 % gel
is indicated for deodorizing malodorous fungating tumors,
and topical MTZ used in this study is recommended as the
standard drug for malodorous fungating wounds in clinical
guidelines [3, 6, 7]. Furthermore, the antibacterial activity of
other forms of topical MTZ against anaerobic bacteria has
been reported in Japan and overseas. It is therefore reasonable
to expect thatMTZ 0.75% gel is safe and effective as a topical
agent for malodorous fungating tumors. The commercializa-
tion of topical MTZ with proven efficacy, safety, and stability
as a formulation will be beneficial even to hospital pharma-
cists who currently prepare special formulations for their
patients.
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